The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Safety of Anacetrapib in Patients with or at High Risk for Coronary Heart Disease
Open accessAbstract
BACKGROUND: Anacetrapib is a cholesteryl ester transfer protein inhibitor that raises high-density lipoprotein (HDL) cholesterol and reduces low-density lipoprotein (LDL) cholesterol. METHODS: We conducted a randomized, double-blind, placebo-controlled trial to assess the efficacy and safety profile of anacetrapib in patients with coronary heart disease or at high risk for coronary heart disease. Eligible patients who were taking a statin and who had an LDL cholesterol level that was consistent with that recommended in guidelines were assigned to receive 100 mg of anacetrapib or placebo daily for 18 months. The primary end points were the percent change from baseline in LDL cholesterol at 24 weeks (HDL cholesterol level was a secondary end point) and the safety and side-effect profile of anacetrapib through 76 weeks. Cardiovascular events and deaths were prospectively adjudicated. RESULTS: A total of 1623 patients underwent randomization. By 24 weeks, the LDL cholesterol level had been reduced from 81 mg per deciliter (2.1 mmol per liter) to 45 mg per deciliter (1.2 mmol per liter) in the anacetrapib group, as compared with a reduction from 82 mg per deciliter (2.1 mmol per liter) to 77 mg per deciliter (2.0 mmol per liter) in the placebo group (P<0.001)--a 39.8% reduction with anacetrapib beyond that seen with placebo. In addition, the HDL cholesterol level increased from 41 mg per deciliter (1.0 mmol per liter) to 101 mg per deciliter (2.6 mmol per liter) in the anacetrapib group, as compared with an increase from 40 mg per deciliter (1.0 mmol per liter) to 46 mg per deciliter (1.2 mmol per liter) in the placebo group (P<0.001)--a 138.1% increase with anacetrapib beyond that seen with placebo. Through 76 weeks, no changes were noted in blood pressure or electrolyte or aldosterone levels with anacetrapib as compared with placebo. Prespecified adjudicated cardiovascular events occurred in 16 patients treated with anacetrapib (2.0%) and 21 patients receiving placebo (2.6%) (P = 0.40). The prespecified Bayesian analysis indicated that this event distribution provided a predictive probability (confidence) of 94% that anacetrapib would not be associated with a 25% increase in cardiovascular events, as seen with torcetrapib. CONCLUSIONS: Treatment with anacetrapib had robust effects on LDL and HDL cholesterol, had an acceptable side-effect profile, and, within the limits of the power of this study, did not result in the adverse cardiovascular effects observed with torcetrapib. (Funded by Merck Research Laboratories; ClinicalTrials.gov number, NCT00685776.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“in humans, elevated cholesterol levels are a major risk factor for the development of cardiovascular disease (Cannon et al., 2010).”
From Population genomics reveal recent speciation and rapid evolutionary adaptation in polar bears (2014) · cites this paper as Cannon et al., 2010
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Grundy, S. M., Cleeman, J. I., Merz, C. N. B., Brewer, H. B., Clark, L. T., Hunninghake, D. B., Pasternak, R. C., Smith, S. C., & Stone, N. J. (2004) · Circulation · doi:10.1161/01.cir.0000133317.49796.0e · Cited by 6,902
Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., Joyal, S. V., Hill, K. A., Pfeffer, M. A., & Skene, A. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040583 · Cited by 4,938
Self-citationIntensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease
LaRosa, J. C., Grundy, S. M., Waters, D. D., Shear, C., Barter, P., Fruchart, J.-C., Gotto, A. M., Greten, H., Kastelein, J. J. P., Shepherd, J., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050461 · Cited by 3,489
Self-citationEffects of torcetrapib in patients at high risk for coronary events
Barter, P. J., Caulfield, M., Eriksson, M., Grundy, S. M., Kastelein, J. J. P., Komajda, M., Lopez-Sendon, J., Mosca, L., Tardif, J.-C., Waters, D. D., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706628 · Cited by 3,139
Self-citationPedersen, T. R. (2005) · JAMA · doi:10.1001/jama.294.19.2437 · Cited by 1,548
Effects of an Inhibitor of Cholesteryl Ester Transfer Protein on HDL Cholesterol
Brousseau, M. E., Schaefer, E. J., Wolfe, M. L., Bloedon, L. T., Digenio, A. G., Clark, R. W., Mancuso, J. P., & Rader, D. J. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa031766 · Cited by 774
Thompson, A. (2008) · JAMA · doi:10.1001/jama.299.23.2777 · Cited by 498
Forrest, M. J., Bloomfield, D. M., Briscoe, R. J., Brown, P. N., Cumiskey, A., Ehrhart, J., Hershey, J. C., Keller, W. J., Ma, X., McPherson, H. E., et al. (2008) · British Journal of Pharmacology · doi:10.1038/bjp.2008.229 · Cited by 293
Krishna, R., Anderson, M. S., Bergman, A. J., Jin, B., Fallon, M. S., Côté, J., Rosko, K., Chavez-Eng, C. M., Lutz, R., Bloomfield, D. M., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61813-3 · Cited by 275
Flagged first, then by citations
Cited by
Sorted by citations
Items 401–500 of 752
Investigational CETP antagonists for hyperlipidemia and atherosclerosis prevention
Sirtori, C. R. (2011) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2011.614946 · Cited by 14
Lipid pharmacotherapy for treatment of atherosclerosis
Nicholls, S. J., Pisaniello, A. D., Kataoka, Y., & Puri, R. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.904287 · Cited by 14
Emerging options in the treatment of dyslipidemias: a bright future?
Florentin, M., Liberopoulos, E. N., Mikhailidis, D. P., & Elisaf, M. (2011) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2011.554395 · Cited by 14
Boffa, M. B. (2016) · Current Atherosclerosis Reports · doi:10.1007/s11883-016-0622-1 · Cited by 15
Is Lipoprotein(a) Ready for Prime-Time Use in the Clinic?
Ellis, K. L., & Watts, G. F. (2018) · Cardiology Clinics · doi:10.1016/j.ccl.2017.12.010 · Cited by 16
Cholesteryl ester transfer protein inhibitors in precision medicine
Su, X., Li, G., Deng, Y., & Chang, D. (2020) · Clinica Chimica Acta · doi:10.1016/j.cca.2020.09.012 · Cited by 14
Ma, S., Xia, M., & Gao, X. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.681444 · Cited by 14
Nicholls, S. J. (2012) · Current Cardiology Reports · doi:10.1007/s11886-012-0252-3 · Cited by 14
Quinoline-3-carboxamide Derivatives as Potential Cholesteryl Ester Transfer Protein Inhibitors
Li, W., Xiong, X., Zhao, D., Shi, Y., Yang, Z., Yu, C., Fan, P.-W., Cheng, M., & Shen, J. (2012) · Molecules · doi:10.3390/molecules17055497 · Cited by 14
Hovingh, G. K., Goldberg, A. C., & Moriarty, P. M. (2017) · Journal of clinical lipidology · doi:10.1016/j.jacl.2017.03.008 · Cited by 14
New Horizons for Cholesterol Ester Transfer Protein Inhibitors
Schwartz, G. G. (2011) · Current Atherosclerosis Reports · doi:10.1007/s11883-011-0217-9 · Cited by 13
Mendelian Randomization Studies in Atherosclerotic Cardiovascular Diseases
Ko, D. S., & Kim, Y. H. (2024) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2024.13.3.280 · Cited by 13
HDL and CETP Inhibition: Will This DEFINE the Future?
Davidson, M. H. (2012) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-012-0191-8 · Cited by 13
Self-citationEffects of anacetrapib on plasma lipids, apolipoproteins and PCSK9 in healthy, lean rhesus macaques
Roddy, T. P., McLaren, D. G., Chen, Y., Xie, D., Dunn, K., Kulick, A. A., Szeto, D., Forrest, G., Albanese, K., Donnelly, M. J., et al. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.04.015 · Cited by 13
Self-citationNovel strategies for managing dyslipidemia: treatment beyond statins
Ling, H., Burns, T. L., & Hilleman, D. E. (2012) · Postgraduate Medicine · doi:10.3810/pgm.2012.11.2612 · Cited by 10
Briand, F., Thiéblemont, Q., Muzotte, E., Burr, N., Urbain, I., Sulpice, T., & Johns, D. G. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.06.022 · Cited by 13
The Ebbs and Flows in the Development of Cholesterol-Lowering Drugs: Prospects for the Future
Hajhosseiny, R., Sabir, I. N., Khavandi, K., & Wierzbicki, A. S. (2014) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2014.76 · Cited by 13
Sahebkar, A., & Watts, G. F. (2014) · Clinical Lipidology · doi:10.2217/clp.14.14 · Cited by 13
Lipoprotein(a): cardiovascular risk and emerging therapies
Fujino, M., & Nicholls, S. J. (2023) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2023.2197593 · Cited by 14
Arsenault, B. J., Kritikou, E. A., & Tardif, J. (2012) · Current Cardiology Reports · doi:10.1007/s11886-012-0285-7 · Cited by 13
Davidson, M. H. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.11.025 · Cited by 13
Self-citationNew promising potential in fighting atherosclerosis: HDL and reverse cholesterol transport
GINTER, E., & Šimko, V. (2013) · Bratislavské lekárske listy/Bratislava medical journal · doi:10.4149/bll_2013_037 · Cited by 12
Lipoprotein apheresis in patients with peripheral artery disease and hyperlipoproteinemia(a)
Poller, W. C., Dreger, H., Morgera, S., Berger, A., Flessenkämper, I., & Enke-Melzer, K. (2015) · Atherosclerosis Supplements · doi:10.1016/j.atherosclerosissup.2015.02.032 · Cited by 12
High-Density Lipoproteins and Coronary Artery Disease
Schaffer, A., Verdoia, M., Barbieri, L., Aprami, T. M., Suryapranata, H., Marino, P. N., & Luca, G. D. (2013) · Angiology · doi:10.1177/0003319713502253 · Cited by 12
Rosenson, R. S., & Köenig, W. (2016) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-016-6642-9 · Cited by 12
Journey Through Cholesteryl Ester Transfer Protein Inhibition
Karalis, I. K., Rensen, P. C. N., & Jukema, J. W. (2013) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.111.000014 · Cited by 12
Cholesteryl Ester Transfer Protein Inhibitors as Agents to Reduce Coronary Heart Disease Risk
Barter, P. J., & Rye, K. (2018) · Cardiology Clinics · doi:10.1016/j.ccl.2017.12.011 · Cited by 12
Self-citationJohns, D. G., Wang, S., Rosa, R. L., Hubert, J. A., Xu, S. S., Chen, Y., Bateman, T. J., & Blaustein, R. O. (2019) · Pharmacology Research & Perspectives · doi:10.1002/prp2.543 · Cited by 12
Lack of an effect of anacetrapib on the pharmacokinetics of digoxin in healthy subjects
Krishna, R., Stypinski, D., Ali, M., Garg, A., Gendrano, I. N., Maes, A. L., DeGroot, B. J., Liu, Y., Li, S., Connolly, S. M., et al. (2011) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.776 · Cited by 12
Genome-wide Screen for Modulation of Hepatic Apolipoprotein A-I (ApoA-I) Secretion
Miles, R. R., Perry, W., Haas, J. V., Mosior, M. K., N'Cho, M., Wang, J. J., Yu, P., Calley, J. N., Yue, Y. G., Carter, Q. L., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.410092 · Cited by 12
Structural and biophysical insight into cholesteryl ester-transfer protein
Hall, J., & Qiu, X. (2011) · Biochemical Society Transactions · doi:10.1042/bst0391000 · Cited by 12
Povsic, T. J., Scott, R. C., Mahaffey, K. W., Blaustein, R. O., Edelberg, J. M., Lefkowitz, M. P., Solomon, S. D., Fox, J. C., Healy, K. E., Khakoo, A. Y., et al. (2017) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-017-6739-9 · Cited by 12
Sloop, G. D., Weidman, J. J., & Cyr, J. A. S. (2015) · Therapeutic Advances in Cardiovascular Disease · doi:10.1177/1753944714566427 · Cited by 12
The evolving role of CETP inhibition: beyond HDL cholesterol
Ray, K. K., & Vallejo‐Vaz, A. J. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60608-0 · Cited by 11
Dislipidemia aterogénica y riesgo residual. Estado de la cuestión en 2014
Núñez-Cortés, J. M., Pedro‐Botet, J., & Pintó, X. (2014) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2014.09.004 · Cited by 11
Therapeutic potential of antisense oligonucleotides for the management of dyslipidemia
Crooke, R. M., & Graham, M. J. (2011) · Clinical Lipidology · doi:10.2217/clp.11.59 · Cited by 11
Arai, H., Teramoto, T., Daida, H., Ikewaki, K., Maeda, Y., Nakagomi, M., Shirakawa, M., Kakikawa, T., Numaguchi, H., Johnson‐Levonas, A. O., et al. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.03.017 · Cited by 11
Qiao, J. X., Wang, T. C., Adam, L. P., Chen, A. Y. A., Taylor, D. S., Yang, R., Zhuang, S., Sleph, P. G., Li, J. P., Li, D., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01363 · Cited by 11
SAR studies on the central phenyl ring of substituted biphenyl oxazolidinone-potent CETP inhibitors
Lu, Z., Chen, Y., Napolitano, J. B., Taylor, G. E., Ali, A., Hammond, M. L., Deng, Q., Tan, E., Tong, X., Xu, S. S., et al. (2011) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2011.11.039 · Cited by 11
Clinical Trials Update AHA Congress 2010
Horowitz, J. D., Rosenson, R. S., McMurray, J. J. V., Marx, N., & Remme, W. J. (2011) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-011-6285-9 · Cited by 11
Schuchardt, M., Tölle, M., & van der Giet, M. (2014) · Handbook of experimental pharmacology · doi:10.1007/978-3-319-09665-0_13 · Cited by 11
HDL as a prognostic biomarker for coronary atherosclerosis: the role of inflammation
Παπαγεωργίου, Ν., Zacharia, E. M., Androulakis, E. S., Briasoulis, Α., Charakida, M., & Tousoulis, D. (2016) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2016.1152264 · Cited by 12
Strategic Integration of In Vivo Cardiovascular Models During Lead Optimization
Fryer, R. M., Harrison, P. C., Muthukumarana, A. C., Mazurek, S. N., Ng, K. J., Chen, R. R., Harrington, K. E., Dinallo, R. M., Chi, L., & Reinhart, G. A. (2011) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0b013e31824485dd · Cited by 11
LDL, HDL, VLDL, and CVD Prevention: Lessons from Genetics?
Hewing, B., & Landmesser, U. (2015) · Current Cardiology Reports · doi:10.1007/s11886-015-0610-z · Cited by 11
Relationship between atorvastatin dose and the harm caused by torcetrapib
Barter, P. J., Rye, K., Beltangady, M. S., Ports, W. C., Duggan, W. T., Boekholdt, S. M., DeMicco, D. A., Kastelein, J. J. P., & Shear, C. L. (2012) · Journal of Lipid Research · doi:10.1194/jlr.p026328 · Cited by 10
Self-citationPage, M. M., Hooper, A. J., & Burnett, J. R. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2016.1129402 · Cited by 10
Success, Failure, and Transparency in Biomarker-Based Drug Development
Hey, S. P., Franklin, J. M., Avorn, J., & Kesselheim, A. S. (2017) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.116.003121 · Cited by 10
Nam, G. E., Huh, Y., Jung, J., Han, K., Kim, S. M., & on Behalf of the Taskforce Team of the Obesity Fact Sheet of the Korean Society for the Study of Obesity (2022) · Endocrinology and Metabolism · doi:10.3803/enm.2021.1259 · Cited by 10
Dislipidemia y riesgo vascular. Una revisión basada en nuevas evidencias
Pallarés‐Carratalá, V., Fuster, V. P., & Rocati, D. V. G. (2015) · Medicina de Familia SEMERGEN · doi:10.1016/j.semerg.2014.10.015 · Cited by 12
Monogenic causes of elevated HDL cholesterol and implications for development of new therapeutics
Larach, D. B., Cuchel, M., & Rader, D. J. (2013) · Clinical Lipidology · doi:10.2217/clp.13.73 · Cited by 10
The beneficial effects of HDL-C on atherosclerosis: rationale and clinical results
Santos‐Gallego, C. G., Torres, F., & Badimón, J. J. (2011) · Clinical Lipidology · doi:10.2217/clp.10.90 · Cited by 10
Zhao, D., Xie, H., Bai, C., Liu, C., Hao, C., Zhao, S., Yuan, H., Luo, C., Wang, J., Lin, B., et al. (2015) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2015.12.010 · Cited by 10
Duivenvoorden, R., & Fayad, Z. A. (2012) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e32835916b3 · Cited by 10
Zhou, J., Zhang, Q., Wang, Y., Gao, P., & Chen, D. (2017) · Postgraduate Medicine · doi:10.1080/00325481.2018.1401421 · Cited by 10
Recent developments in modulating atherogenic lipoproteins
White, C. R., Goldberg, D., & Anantharamaiah, G. M. (2015) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000216 · Cited by 10
Androulakis, E. S., Zacharia, E. M., Παπαγεωργίου, Ν., Lioudaki, E., Bertsias, D., Charakida, M., Siasos, G., & Tousoulis, D. (2017) · Current Cardiology Reviews · doi:10.2174/1573403x13666170209145622 · Cited by 10
CETP Inhibition: Does the Future Look Promising?
Toth, P. P. (2011) · Current Cardiology Reports · doi:10.1007/s11886-011-0218-x · Cited by 9
Sinning, D., Leistner, D. M., & Landmesser, U. (2016) · Herz · doi:10.1007/s00059-016-4430-8 · Cited by 9
Reduction of cardiovascular risk in subjects with high lipoprotein (a) levels
Malaguarnera, G., Latteri, S., Catania, V. E., & Malaguarnera, M. (2017) · Journal of Thoracic Disease · doi:10.21037/jtd.2017.08.67 · Cited by 9
Sanz, J., & Fuster, V. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.03.052 · Cited by 9
Anacetrapib, a cholesteryl ester transfer protein inhibitor
Hooper, A. J., & Burnett, J. R. (2011) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2012.642499 · Cited by 9
Novel Therapies for Low-Density Lipoprotein Cholesterol Reduction
Toth, P. P. (2016) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2016.05.028 · Cited by 9
Krishna, R., Stypinski, D., Ali, M., Garg, A. X., Côté, J., Maes, A. L., DeGroot, B. J., Liu, Y., Li, S., Connolly, S. M., et al. (2012) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2012.04171.x · Cited by 9
Targeting Lipoprotein (a): an Evolving Therapeutic Landscape
Man, L. C., Kelly, E. M., & Duffy, D. (2015) · Current Atherosclerosis Reports · doi:10.1007/s11883-015-0502-0 · Cited by 9
Contemporary and Novel Therapeutic Options for Hypertriglyceridemia
Bell, D. A., & Watts, G. F. (2015) · Clinical Therapeutics · doi:10.1016/j.clinthera.2015.08.001 · Cited by 9
Promising new therapies for the treatment of hypercholesterolemia
Valerio, M. G., Velayati, A., Jain, D., & Aronow, W. S. (2016) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2016.1148136 · Cited by 9
Safety of Anacetrapib in Patients with or at High Risk for Coronary Heart Disease
Gersh, B. J. (2011) · Yearbook of Medicine · doi:10.1016/s0084-3873(11)00276-8 · Cited by 9
Claudia, F. G., Marcelo, B., & Giselle, H. R. (2012) · 老年心脏病学杂志：英文版 · doi:10.3724/sp.j.1263.2011.12292 · Cited by 9
Is there a link between diabetes and cholesterol metabolism?
Besseling, J., & Hutten, B. A. (2015) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.2016.1133292 · Cited by 9
Naim, M. A. A. Z., Sumida, K., Streja, E., Thomas, F., Davis, R. L., Kalantar‐Zadeh, K., & Kovesdy, C. P. (2026) · Drugs · doi:10.1007/s40265-025-02275-w · Cited by 8
Miyares, M. A., & Davis, K. (2012) · Vascular Health and Risk Management · doi:10.2147/vhrm.s29010 · Cited by 8
Anderson, T. J. (2015) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2015.03.019 · Cited by 8
Emerging PCSK9 inhibitors for treating dyslipidaemia: buttressing the gaps in coronary prevention
Page, M. M., & Watts, G. F. (2015) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2015.1035709 · Cited by 8
No cardiovascular benefit with evacetrapib – is this the end of the road for the ‘cetrapibs’?
Doggrell, S. A. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1365838 · Cited by 8
Antilipidemic Drug Therapy Today and in the Future
Kramer, W. (2015) · Handbook of experimental pharmacology · doi:10.1007/164_2015_15 · Cited by 8
Colin, S., Chinetti, G., Kuivenhoven, J. A., & Staels, B. (2014) · Handbook of experimental pharmacology · doi:10.1007/978-3-319-09665-0_20 · Cited by 8
Drug targets beyond HMG-CoA reductase: Why venture beyond the statins?
Gelissen, I. C., & Brown, A. J. (2011) · Frontiers in Biology · doi:10.1007/s11515-011-1130-x · Cited by 8
Anacetrapib as a potential cardioprotective strategy
Bartolo, B. A. D., & Nicholls, S. J. (2017) · Drug Design Development and Therapy · doi:10.2147/dddt.s114104 · Cited by 8
Roberts, C. K. (2014) · CRC Press eBooks · doi:10.1201/b16783-5 · Cited by 8
ASSOCIATION OF LIPID FRACTIONS LEVELS WITH CARDIOVASCULAR DISEASE
Rada, F. H. (2017) · Asian Journal of Pharmaceutical and Clinical Research · doi:10.22159/ajpcr.2017.v10i3.15984 · Cited by 8
How will new medications affect the lipoprotein apheresis situation in Germany?
Parhofer, K. G. (2013) · Atherosclerosis Supplements · doi:10.1016/j.atherosclerosissup.2012.10.022 · Cited by 7
Is the Future of Statins Aligned with New Novel Lipid Modulation Therapies?
Phan, B. A. P., & Toth, P. P. (2013) · Current Atherosclerosis Reports · doi:10.1007/s11883-012-0300-x · Cited by 7
Novel Therapies for Familial Hypercholesterolemia
Parizo, J. T., Sarraju, A., & Knowles, J. W. (2016) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-016-0486-2 · Cited by 7
Wang, Z., Niimi, M., Ding, Q., Liu, Z., Wang, L., Zhang, J., Xu, J., & Fan, J. (2017) · PLoS ONE · doi:10.1371/journal.pone.0180772 · Cited by 7
Bitam, S., Hamadache, M., & Salah, H. (2020) · SAR and QSAR in environmental research · doi:10.1080/1062936x.2020.1765195 · Cited by 7
Cheng, L., Zhang, L., Liu, J., Li, W., Bai, X., Li, R., Li, B., Wang, L., Zhou, J., Wu, Y., et al. (2020) · Disease Markers · doi:10.1155/2020/7054596 · Cited by 7
Lipoprotein and Lipid Metabolism
Hegele, R. A. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-383834-6.00100-2 · Cited by 8
Möglichkeiten und Grenzen der modernen Lipidtherapie
Klose, G. (2011) · Der Internist · doi:10.1007/s00108-010-2799-7 · Cited by 7
Arsenault, B. J., Boekholdt, S. M., Tardif, J., & Kastelein, J. J. P. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr408 · Cited by 7
Reducing the Cardiovascular Disease Burden
Bikdeli, B., & Barreto‐Filho, J. A. (2012) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.111.964072 · Cited by 7
High-density lipoprotein: quantity or quality?
Τζιόμαλος, Κ. (2016) · Journal of Thoracic Disease · doi:10.21037/jtd.2016.11.67 · Cited by 7
Sucharski, H. C., & Koenig, S. N. (2022) · Springer eBooks · doi:10.1007/978-3-031-08309-9_12 · Cited by 6
Evaluating obicetrapib as an emerging treatment for patients with dyslipidemia: a game changer?
Nicholls, S. J., Tan, S., Butters, J., & Nelson, A. J. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2409324 · Cited by 6
Ongoing challenges for pharmacotherapy for dyslipidemia
Pisaniello, A. D., Scherer, D. J., Kataoka, Y., & Nicholls, S. J. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.986094 · Cited by 6
Infusional high-density lipoproteins therapies as a novel strategy for treating atherosclerosis
Bartolo, B. A. D., Schwarz, N., Andrews, J., & Nicholls, S. J. (2016) · Archives of Medical Science · doi:10.5114/aoms.2016.60941 · Cited by 6
Lagerstedt, J. O., Dalla‐Riva, J., Marinković, G., Giudice, R. D., Engelbertsen, D., Burlin, J., Petrlová, J., Lindahl, M., Bernfur, K., Melander, O., et al. (2018) · Journal of Internal Medicine · doi:10.1111/joim.12817 · Cited by 6
McEvoy, J. W., Whelton, S. P., & Blumenthal, R. S. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-42973-3.00038-x · Cited by 6
Paragh, G., Zilahi, P., Kolozsvári, L. R., Lőrincz, H., Fülöp, P., & Harangi, M. (2024) · Life · doi:10.3390/life14030374 · Cited by 6
Tani, S., Nagao, K., & Hirayama, A. (2012) · American Journal of Cardiovascular Drugs · doi:10.1007/bf03261844 · Cited by 6
Emerging Therapeutic Approaches to Treat Dyslipidemia
Preiss, D., & Packard, C. J. (2014) · Current Cardiology Reports · doi:10.1007/s11886-014-0506-3 · Cited by 6
Metadata
- Authors
- Cannon, C. P., Shah, S., Dansky, H. M., Davidson, M., Brinton, E. A., Gotto, A. M., Stepanavage, M., Liu, S. X., Gibbons, P., Ashraf, T. B., Zafarino, J., Mitchel, Y., & Barter, P.
- Affiliations
- Brigham and Women's Hospital (US)
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Radiant Research (United States) (US)
- University of Utah (US)
- The Heart Research Institute (AU)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2010-12-16
- Volume
- 363
- Issue
- 25
- Pages
- 2406-2415
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2090464684
- Cited by
- 749
- References
- 17
- Citations by year
- 2026: 13 · 2025: 7 · 2024: 13 · 2023: 13 · 2022: 16 · 2021: 18 · 2020: 18 · 2019: 21 · 2018: 26 · 2017: 54 · 2016: 68 · 2015: 83 · 2014: 83 · 2013: 92 · 2012: 116
- FWCI
- 107.18
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Keywords
- anacetrapib, cholesteryl ester transfer protein inhibitors, coronary artery disease, LDL cholesterol lowering, HDL cholesterol, statin combination therapy, cardiovascular safety, cardiovascular events, drug safety, high-risk patients, lipid-lowering therapy, blood pressure, electrolytes, aldosterone, Bayesian hierarchical model, cardiovascular hospitalization
- MeSH terms
- Adult, Aged, Anticholesteremic Agents, Bayes Theorem, Combined Modality Therapy, Coronary Disease, Double-Blind Method, Female, Humans, Cholesterol, HDL, Cholesterol, LDL, Male, Middle Aged, Risk Factors, Oxazolidinones, Cholesterol Ester Transfer Proteins, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
